Skin Localization of Cow’s Milk Proteins Delivered by a New Ready-to-Use Atopy Patch Test

Soury, D.; Barratt, Gillian; Ah‐Leung, S.; Legrand, Patrick; Chacun, Hélène; Ponchel, Gilles

doi:10.1007/s11095-005-5881-4

Cited by 15 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Perspiration generated under an occlusive chamber dissolves the lyophilised allergen protein loaded on the Viaskin® EDS [57, 58]. Delivered via such EDS, proteins have been demonstrated to accumulate in the stratum corneum, where they efficiently targets immune cells of the superficial skin layer [60] that rapidly migrate to the draining lymph nodes [57]. In murine studies, EPIT using the Viaskin® EDS showed efficacy equivalent to SCIT in preventing allergic airway reactions upon inhalative allergen challenge [57].…”

Section: Discussionmentioning

confidence: 99%

Epicutaneous Immunotherapy for Aeroallergen and Food Allergy

Senti

Moos

Kündig

2013

Curr Treat Options Allergy

View full text Add to dashboard Cite

Opinion statementIgE-mediated allergies today affect up to 30 % of the population in industrialized countries. Allergen immunotherapy is the only disease-modifying treatment option with a long-term effect. However, very few patients (<5 %) choose immunotherapy, due to the long treatment duration (between 3–5 years) and possible local and systemic allergic side effects of the allergen administrations. The latter occur when an allergen accidentally reaches the blood circulation. Therefore, the ideal application route for allergen immunotherapy should be characterized by two hallmarks: firstly, by a high number of potent antigen-presenting cells, which enhance efficacy and thus shorten treatment duration. Secondly, the allergen administration site is ideally non-vascularized, so that inadvertent systemic distribution of the allergen and consequent systemic allergic side effects are minimized. The epidermis contains high numbers of potent antigen-presenting Langerhans cells and, as an epithelium, is non-vascularized. Therefore, the epidermis represents an interesting administration route. Historical evidence for the clinical efficacy of epicutaneous allergy immunotherapy (EPIT) has now been strengthened by a number of recent double-blinded placebo-controlled clinical trials performed by independent groups. We review the immunological rationale, history and clinical experience with epicutaneous allergy immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Epicutaneous Immunotherapy for Aeroallergen and Food Allergy

Senti

Moos

Kündig

2013

Curr Treat Options Allergy

View full text Add to dashboard Cite

show abstract

“…When applied onto intact skin, the EDS preserves its architecture, including the more superficial layers. Experiments with labeled Ags in in vitro transdermal models have shown that this EDS allows native protein to concentrate inside the stratum corneum within the vicinity of immunological cells, without passage through the skin (7).…”

mentioning

confidence: 99%

Epicutaneous Immunotherapy Results in Rapid Allergen Uptake by Dendritic Cells through Intact Skin and Downregulates the Allergen-Specific Response in Sensitized Mice

Dioszeghy

Mondoulet

Dhelft

et al. 2011

The Journal of Immunology

145

131

View full text Add to dashboard Cite

Epicutaneous immunotherapy onto intact skin has proved to be an efficient and safe alternative treatment of allergy in an animal model with various allergens and in children for cow’s milk allergy. The aim of this study was to analyze the different steps of the immunological handling of the allergen when deposited on intact skin using an epicutaneous delivery system and its immune consequences in sensitized BALB/c mice. As expected, when applied on intact skin, OVA exhibits neither a passive passage through the skin nor any detectable systemic delivery. The current study demonstrates that, after a prolonged application on intact skin, OVA is taken up by dendritic cells in the superficial layers of the stratum corneum and transported, after internalization, to the draining lymph nodes, with variations according to the previous level of sensitization of the mice. When OVA is applied with the epicutaneous delivery system repeatedly, specific local and systemic responses are down-modulated in association with the induction of regulatory T cells. Besides providing new insights into skin function in the presence of allergens, this study indicates that the skin might have a tolerogenic role, at least when kept intact.

show abstract

“…Whole protein, delivered via such a system, has been demonstrated to accumulate in the stratum corneum, from where it diffuses down to immune cells in the viable layers of the epidermis. 46,71,72 Murine studies, designed to test therapeutic efficacy of the Viaskin ® EDS, demonstrated equivalence of EPIT and SCIT 46 as well as EPIT and SLIT 73 in preventing allergic airway reactions upon airway allergen challenge. Moreover, EPIT using the Viaskin ® EDS was also efficient in the treatment of food allergy as measured by prevention of mast cell degranulation upon oral allergen challenge.…”

Section: Epicutaneous Immunotherapy (Epit)mentioning

confidence: 99%